- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Background Information on Recurrent C. Difficile Infections
Panelist discusses how recurrent Clostridioides difficile infection results from persistent microbiome disruption, where antibiotic-induced dysbiosis enables bacterial overgrowth and toxin production. Characterized by repeated episodes of colitis, it predominantly affects older, hospitalized patients with compromised immune systems, presenting significant clinical challenges through inflammatory complications and potential systemic spread.
EP: 1.The Role of Testing for C Difficile in Clinical Practice
EP: 2.Utilizing Antibiotics in Treatment of C Difficile
EP: 3.Examining FMT for Patients With Recurrent C Difficile infections
EP: 4.Exploring Rebyota for Recurrent C Difficile Infections
EP: 5.Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
EP: 6.Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
EP: 7.Management of Recurrent C Difficile Infections in the Future
EP: 8.Key Background Information on Recurrent C. Difficile Infections
EP: 9.Importance of Early Detection of Recurrent C Difficile Infections
EP: 10.Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life
EP: 11.Diagnosis of Recurrent C Difficile Infections
EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections
EP: 13.Unmet Needs With Recurrent C Difficile Infections
Video content above is prompted by the following:
- Describe the pathophysiology of recurrent C difficile infection and what the potential complications of recurrent C difficile include.
- What is the role of the microbiome?
- Discuss the epidemiology and the risk factors for developing recurrent C difficile infection.
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
